Researcher
Diether Lambrechts
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
Affiliations
- Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Lambrechts Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory of Translational Genetics (VIB-KU Leuven) (Division)
Member
From1 Jan 2012 → Today - Centre for Molecular and Vascular Biology (Division)
Member
From1 Oct 2003 → 30 Sep 2005 - Department of Cellular and Molecular Medicine (Department)
Member
From1 Oct 1999 → 30 Sep 2003
Projects
1 - 10 of 72
- Liquid biopsy and HRD testing in ovarian cancerFrom4 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Decoding the penile cancer tumor microenvironment: heterogeneity of tumor-associated epithelial cell states, it's relationship with HPV, and it's role in prognosis and therapy response.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Integration of Spatial Transcript- and Proteomics Techniques with Pan-cancer single cell RNA-sequencing data to interrogate the impact of immunotherapy on the Tumor Microenvironment (TME)From9 May 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- An Integrated Spatial Atlas of the Tumor Micro-environment of Early Non-Small Cell Lung CancerFrom16 Mar 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Abemaciclib and letrozole in ER positive rare ovarian cancerFrom1 Mar 2023 → TodayFunding: Foundations, funds and other with scientific goal
- SymBioSys: Computationally mapping genomic heterogeneity from long read sequencing dataFrom1 Oct 2022 → TodayFunding: BOF - projects
- Refining the role of dual checkpoint inhibition in advanced lung cancer: a single-cell approachFrom5 Oct 2021 → TodayFunding: FWO Strategic Basic Research Grant
- Multiomic Integration of cell-free DNA profiles to Advance Disease OutcomeFrom1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Connecting Single-cell Immune Profiling in Peripheral Blood with Intratumoral T Cell Expansion in Breast Cancer Upon Checkpoint ImmunotherapyFrom24 Aug 2021 → TodayFunding: FWO Strategic Basic Research Grant
- Developing personalized treatment for advanced penile cancer trough establishment of Patient-Derived Tumor Xenografts (PDTXs).From9 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
11 - 20 of 610
- Integrated analysis of transcriptomic and proteomic alterations in mouse models of ALS/FTD identify early metabolic adaptions with similarities to mitochondrial dysfunction disorders(2024)
Authors: Ingrid Arijs, Diether Lambrechts
Pages: 135 - 149 - Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients.(2024)
Authors: Diether Lambrechts, Els Wauters
Pages: 181 - 206 - Ethanol induces replication fork stalling and membrane stress in immortalized laryngeal cells(2023)
Authors: Lore Hoes, Karin Voordeckers, Rüveyda Dok, Bram Boeckx, Sander Govers, Diether Lambrechts, Sandra Nuyts, Kevin Verstrepen
- Tumor endothelial cell autophagy is a key vascular-immune checkpoint in melanoma(2023)
Authors: Francesca Rizzollo, Johan Van Weyenbergh, Oliver Bechter, Francesca Bosisio, Diether Lambrechts, Gabriele Bergers, Patrizia Agostinis
- Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel(2023)
Authors: Diether Lambrechts, Ines Nevelsteen
Pages: 1186 - 1197 - PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma(2023)
Authors: Sarah Cappuyns, Bram Boeckx, Ingrid Arijs, Aurelie Mechels, Baki Topal, Chris Verslype, Diether Lambrechts, Jeroen Dekervel
- Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma(2023)
Authors: Lise Finotto, Basiel Cole, Maxime Vanmechelen, Bram Boeckx, Diether Lambrechts, Ludo Van Den Bosch, Steven De Vleeschouwer, Frederik De Smet
- ESTABLISHING A CLINICALLY RELEVANT MOUSE MODEL OF MESENCHYMAL GLIOBLASTOMA FOR STUDYING TME TARGETING TREATMENTS.(2023)
Authors: Ingrid Arijs, Diether Lambrechts, Frederik De Smet
- Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells(2023)
Authors: Diether Lambrechts, Ingrid Arijs
- Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers(2023)
Authors: Diether Lambrechts, Ingrid Arijs
Pages: 1327 - 1338
Patents
1 - 10 of 10
- Predicting chronic allograft injury through age-related dna methylation (Inventor)
- Disease detection in liquid biopsies (Inventor)
- Retrotransposon biomarkers (Inventor)
- Detection of ovarian cancer in liquid biopsies (Inventor)
- Markers for determining tumor hypoxia (Inventor)
- Disease detection in liquid biopsies (Inventor)
- Predicting chronic allograft injury through age-related dna methylation (Inventor)
- Predicting age using dna methylation signatures (Inventor)
- Retrotransposon biomarkers (Inventor)
- Predicting chronic allograft injury through ischemia-induced dna methylation (Inventor)